TP53mutations are ubiquitous in high‐grade serous ovarian carcinomas (HGSOC), and the presence ofTP53mutation discriminates between high and low‐grade serous carcinomas and is now an important biomarker for clinical trials targeting mutant p53. p53 immunohistochemistry (IHC) is widely used as a ...
given that several p53-targeting agents currently in clinical trials have differential activity against specific mutations,48 our findings illustrate the potential benefit of systematically identifying TP53 mutations in myeloid neoplasms to identify patients who might benefit from this and other mutation-speci...
Chronic lymphocytic leukaemia (CLL) is a B-cell malignancy with a highly variable clinical course. Whereas some patients require treatment relatively soon after diagnosis, others may stay free of symptoms for many years with a standard ‘watch and wait’ surveillance approach. Genomic analysis of as...
14. Shepherd F A, Lacas B, Le Teuff G, et al.Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer ...
TP53 mutation occurs in approximately 40% to 50% of sporadic CRCs,37, 38, 39 and KPT-330 and AZD6738 are in clinical trials in solid tumors, with data from the former showing clinical activity with an acceptable safety profile.19 We also demonstrated that palbociclib, which is approved for...
Allan JN, Shanafelt T, Wiestner A, et al. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukemia (CLL) with 4 years of follow-up in patients with TP53 aberrations (del(17p) or TP53 mutation): a pooled analysis from 4 clinical trials. Blood. 2020; 136 (...
Whether EGFR mutation combined with TP53 mutation affects the sensitivity of lung cancer cells to tyrosine kinase inhibitor (TKI) and long-term prognosis of non-small cell lung cancer (NSCLC) patients is still unknown and has attracted more attentions. However, in the current clinical practice, ...
However, recent clinical studies with dasatinib in other malig- nancies have shown its efficacy not only irrespective of TP53 status as a single agent (Bosco et al, 2012) but also to overcome TP53 mutation status-related chemoresistance (Amrein et al, 2008). The results of these clinical ...
This should be confirmed by additional retrospective cohort studies and by the incorporation of P53 status in ongoing and future clinical trials. The evaluation of p53 oBarry IacopettaDepartment of SurgeryHuman MutationIacopetta B.TP53 mutation in colorectal cancer. Human Mutation . 2003...
correct assessment ofTP53mutation status, but also physicians in the appropriate understanding of the lab reports, thus decreasing the risk of misinterpretation and incorrect management of patients in routine practice whilst also leading to improved stratification of patients with CLL in clinical trials. ...